LIGAND PHARMACEUTICALS (LGND) Stock Income Statement
NASDAQ:LGND - Nasdaq - US53220K5048 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 181.49M | 167.13M | 131.31M | 196.20M | 277.10M | |||
| Minority Interest Expense | N/A | N/A | N/A | N/A | N/A | |||
| Cost Of Goods | 13.05M | 11.00M | 11.00M | 52.80M | 62.20M | |||
| Gross Profit | 168.45M | 156.06M | 120.80M | 143.40M | 215.00M | |||
| Operating Expenses | 186.26M | 132.94M | 110.22M | 140.40M | 136.00M | |||
| Research and Development | 65.54M | 21.43M | 24.54M | 36.10M | 69.00M | |||
| Selling, General, and Administrative Expenses | 87.00M | 79.00M | 53.00M | 70.10M | 57.50M | |||
| Operating Income | -16.81M | 23.05M | 9.78M | 3.00M | 78.90M | |||
| Interest Income/Expense | -58.68M | 64.99M | 53.67M | 28.80M | -22.70M | |||
| Other Income/Expense | -55.21M | -55.00M | -2.05M | 0.00 | -1.60M | |||
| Non Recurring Items | N/A | -31.00M | 2.22M | 4.20M | -7.30M | |||
| Income Before Taxes | -160.34M | 2.52M | 64.00M | 36.00M | 47.30M | |||
| Income Tax | -28.01M | 6.55M | 9.84M | 41.20M | -9.80M | |||
| Net Income | -132.17M | -4.03M | 52.00M | -33.40M | 57.10M | |||
| EBITDA | 18.19M | 58.05M | 46.78M | 54.50M | 130.00M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -7.12 | -0.22 | 2.88 | -1.97 | 3.31 | |||
| Non GAAP EPS | 5.84 | 5.71 | 6.10 | 4.28 | 6.42 | |||
| Statistics | ||||||||
| Gross Profit Margin | 92.81% | 93.37% | 91.99% | 73.09% | 77.59% | |||
| Profit Margin | -72.83% | -2.41% | 39.60% | -17.02% | 20.61% | |||
| Operating Profit Margin | -9.26% | 13.79% | 7.45% | 1.53% | 28.47% | |||
All data in USD